Company intelligence / Profile preview
Elixiron Immunotherapeutics
Taipei/Nangang District, Taipei City, Taiwanelixiron.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Elixiron is a clinical-stage biotech company with two lead assets in the clinic. Enrupatinib, an oral CSF1R inhibitor, is in Phase II trials for Alzheimer’s disease and has shown robust blood-brain barrier penetration and microglia depletion in preclinical models. Indemakitug targets IFNγ for immunological diseases such as vitiligo and hemophagocytic lymphohistiocytosis. The company has outlicensed two programs and won multiple awards from the Alzheimer’s Association.
- Therapeutic areas
- DermatologyOncologyNeurologyHematology
- Modalities
- Small moleculesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Has secured at least two outlicensing agreements; specific partners not named publicly.
Beyond the preview
Go deeper on Elixiron Immunotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elixiron Immunotherapeutics.